PMID- 36282321 OWN - NLM STAT- MEDLINE DCOM- 20230706 LR - 20230706 IS - 1943-7730 (Electronic) IS - 0007-5027 (Linking) VI - 54 IP - 4 DP - 2023 Jul 5 TI - Association of CEA, NSE, CYFRA 21-1, SCC-Ag, and ProGRP with Clinicopathological Characteristics and Chemotherapeutic Outcomes of Lung Cancer. PG - 372-379 LID - 10.1093/labmed/lmac122 [doi] AB - OBJECTIVE: The aim of this study was to investigate the association of serum carcinoembryonic antigen (CEA), nerve-specific enolase (NSE), cytokeratin 19 fragment (CYFRA21-1), squamous cell carcinoma antigen (SCC-Ag), and pro-gastrin-releasing peptide (ProGRP) with the clinicopathological characteristics and chemotherapeutic outcomes of patients with lung cancer. METHODS: A total of 189 patients with lung cancer (lung cancer group) diagnosed at the Fourth Affiliated Hospital of Anhui Medical University from January 2020 to December 2021 were included. During the same period, 199 patients with benign lung disorders were included as the benign lung disease group and 75 healthy people were selected as the control group. The serum concentrations of CEA, NSE, CYFRA21-1, SCC-Ag, and ProGRP in all the 3 groups were analyzed and compared in patients with different lung cancer tumor-node-metastasis (TNM) stages and pathological classifications. A total of 11 patients with small cell lung cancer (SCLC) and 18 patients with lung adenocarcinoma (LAC) were further evaluated for the dynamic changes of CEA, NSE, CYFRA21-1, SCC-Ag, and ProGRP before chemotherapy and during the 6 courses of chemotherapy, and the outcome of chemotherapy was evaluated every 2 courses. RESULTS: The serum concentrations of CEA, NSE, CYFRA21-1, SCC-Ag, and ProGRP in the lung cancer group were significantly higher than those in the control group (P < .05). We found statistically significant differences in serum CEA, NSE, CYFRA 21-1, SCC-Ag, and ProGRP among patients with different pathological types (LAC, squamous cell carcinoma, or SCLC) and different stages (I-IV). The ProGRP and NSE had the highest expression in SCLC, CEA showed the highest expression in LAC, whereas CYFRA21-1 and SCC-Ag showed the highest expression in lung squamous cell carcinoma (LSCC). The concentrations of all the markers were elevated in the advanced pathological stages. The receiver operating characteristic curve analysis showed that the diagnostic value of the combined detection of CEA, NSE, CYFRA 21-1, SCC-Ag, and ProGRP for lung cancer was significantly higher than using a single biomarker (P < .05). Our dynamic monitoring results show that ProGRP progressively decreased in remission cases of SCLC and CEA progressively decreased in LAC remission cases. CONCLUSION: CEA, NSE, CYFRA 21-1, SCC-Ag, and ProGRP have good clinical value in the early diagnosis, differential diagnosis, and progression monitoring of lung cancer. The ProGRP and CEA concentrations are beneficial for evaluating the outcome of chemotherapy in SCLC and LAC. The combined detection of multiple biomarkers shows improved clinical value in the early diagnosis of lung cancer. CI - (c) The Author(s) 2022. Published by Oxford University Press on behalf of American Society for Clinical Pathology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Bi, Huijuan AU - Bi H AD - Department of Clinical Laboratory, Anhui Public Health Clinical Center, The First Affiliated Hospital of Anhui Medical University North District, Hefei, China. FAU - Yin, Lina AU - Yin L AD - Department of Clinical Laboratory, Anhui Public Health Clinical Center, The First Affiliated Hospital of Anhui Medical University North District, Hefei, China. FAU - Fang, Wenhao AU - Fang W AD - Department of Clinical Laboratory, Anhui Public Health Clinical Center, The First Affiliated Hospital of Anhui Medical University North District, Hefei, China. FAU - Song, Shenglan AU - Song S AD - Department of Clinical Laboratory, Anhui Public Health Clinical Center, The First Affiliated Hospital of Anhui Medical University North District, Hefei, China. FAU - Wu, Shan AU - Wu S AD - Department of Oncology, Anhui Public Health Clinical Center, The First Affiliated Hospital of Anhui Medical University North District, Hefei, China. FAU - Shen, Jilu AU - Shen J AD - Department of Clinical Laboratory, Anhui Public Health Clinical Center, The First Affiliated Hospital of Anhui Medical University North District, Hefei, China. LA - eng GR - GXXT-2020-016/University Cooperation and Public Health Collaborative Innovation Project of Anhui Provincial Department of Education/ GR - 2021zhyx-C55/Anhui Institute of Translational Medicine/ PT - Journal Article PL - England TA - Lab Med JT - Laboratory medicine JID - 0250641 RN - 0 (squamous cell carcinoma-related antigen) RN - 0 (antigen CYFRA21.1) RN - 0 (Keratin-19) RN - 0 (pro-gastrin-releasing peptide (31-98)) RN - 0 (Carcinoembryonic Antigen) RN - 0 (Biomarkers, Tumor) RN - 0 (Antigens, Neoplasm) RN - EC 4.2.1.11 (Phosphopyruvate Hydratase) SB - IM MH - Humans MH - Keratin-19 MH - Carcinoembryonic Antigen MH - Biomarkers, Tumor MH - *Lung Neoplasms/diagnosis/drug therapy MH - Antigens, Neoplasm MH - *Lung Diseases MH - Phosphopyruvate Hydratase MH - *Carcinoma, Squamous Cell/diagnosis/drug therapy OTO - NOTNLM OT - chemotherapy OT - cytokeratin 19 fragment OT - lung cancer OT - neuron-specific enolase OT - pro-gastrin-releasing peptide OT - squamous cell carcinoma antigen EDAT- 2022/10/26 06:00 MHDA- 2023/07/06 06:42 CRDT- 2022/10/25 11:14 PHST- 2023/07/06 06:42 [medline] PHST- 2022/10/26 06:00 [pubmed] PHST- 2022/10/25 11:14 [entrez] AID - 6772479 [pii] AID - 10.1093/labmed/lmac122 [doi] PST - ppublish SO - Lab Med. 2023 Jul 5;54(4):372-379. doi: 10.1093/labmed/lmac122.